Urogenital Neoplasms  >>  Halaven (eribulin mesylate)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
NCT00278993 / 2005-004271-37: Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Completed
2
108
US
E7389
Eisai Inc.
Prostate Cancer
01/08
01/08
NCT00337077: Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Completed
2
121
US
eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog
National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
06/09
11/13
NCT00334893: Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Completed
2
74
US
eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog
National Cancer Institute (NCI)
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
03/12
03/12

Download Options